



LOMA LINDA  
UNIVERSITY  
HEALTH

# Association between procalcitonin levels and *Clostridium difficile* infection

Kelly Ishizuka, PharmD<sup>1</sup>, Allison Uniat<sup>1</sup>, Lee Nguyen, PharmD, BCPS-AQ ID<sup>1</sup>, Lisa Hong, PharmD, BCPS<sup>1</sup>  
Loma Linda University School of Pharmacy<sup>1</sup>, Loma Linda, CA

## BACKGROUND

- Elevation in procalcitonin (PCT) has been correlated to infections caused specifically by bacteria
- PCT levels have been used to assist in diagnoses and guidance of antibiotic therapy in respiratory tract infections as well as sepsis
- Rao K, et al. published the only study evaluating the association between PCT levels and *Clostridium difficile* infection (CDI) severity, which showed an association present with a PCT cutoff of 0.2 mcg/L

## OBJECTIVE

- Determine the association between CDI and PCT
- Evaluate association between CDI severity and PCT
- Determine individual severity factors associated with increased PCT

## ENDPOINTS

### Primary endpoint:

- PCT in patients with completed CDI diagnostic tests

### Secondary endpoints:

- PCT levels of patients with different severity levels
  - Mild-moderate: WBC <15,000 cells/μL and SCr <1.5x baseline
  - Severe: WBC ≥15,000 cells/μL or SCr >1.5x baseline
  - Severe, complicated: hypotension, shock, ileus, megacolon

## METHODS

Retrospective chart review of Loma Linda University Medical Center's electronic medical records from January 1, 2013 to September 30, 2015.

Table 1. Patient Population

| INCLUSION   | EXCLUSION   |
|---|---|
| <input type="checkbox"/> Suspected <i>Clostridium difficile</i> infection | <input type="checkbox"/> Younger than 18 years old or older than 89 years |
| <input type="checkbox"/> PCT level drawn on day of suspected CDI          | <input type="checkbox"/> No PCT levels                                    |
|   | <input type="checkbox"/> Pregnant or incarcerated                         |
|   | <input type="checkbox"/> Expired within 2 days of CDI diagnostic tests    |

Table 2. Baseline Characteristics

|                         | On Admission        |                     |         | Day of Diagnostic Tests |                     |         |
|-------------------------|---------------------|---------------------|---------|-------------------------|---------------------|---------|
|                         | Positive CDI (n=55) | Negative CDI (n=49) | P-value | Positive CDI (n=55)     | Negative CDI (n=49) | P-value |
| Age (years)*            | 64 (19-89)          | 63 (18-89)          | 0.511   | -                       | -                   | -       |
| Males (n)(%)            | 25 (45%)            | 24 (49%)            | 0.844   | -                       | -                   | -       |
| Weight (kg)*            | 75.8 (44.5-163.1)   | 66.8 (28.4-129)     | 0.130   | -                       | -                   | -       |
| Height (cm)*            | 162.6 (15.2-185.4)  | 160 (15.2-185.4)    | 0.457   | -                       | -                   | -       |
| Highest temp (F)*       | 99 (97.2-104.1)     | 98.8 (97.6-104)     | 0.527   | 99.3 (97.2-104.1)       | 98.9 (97.6-104)     | 0.395   |
| Lowest SBP (mmHg)*      | 102 (68-155)        | 108 (61-192)        | 0.532   | 98 (64-127)             | 100 (61-140)        | 0.625   |
| Lowest DBP (mmHg)*      | 59 (25-89)          | 59 (28-93)          | 0.757   | 52 (16-77)              | 49 (21-82)          | 0.848   |
| WBC (bil/L)*            | 14.34 (0.13-91.38)  | 12.76 (0.9-46.7)    | 0.147   | 16.45 (1.68-82.4)       | 12.72 (0.9-41.9)    | 0.027   |
| SCr (mg/dL)*            | 0.95 (0.3-10.1)     | 1.2 (0.3-7.9)       | 0.198   | 1.15 (0.3-10.1)         | 1.05 (0.3-7.3)      | 0.453   |
| Albumin (g/dL)*         | 3 (1.5-4.3)         | 3.2 (1.6-4.7)       | 0.087   | 2.6 (1.7-3.7)           | 3 (1.4-4)           | 0.137   |
| Lactate (mmol/L)*       | 1.9 (0.6-10.5)      | 2.15 (0.6-8.7)      | 0.643   | 1.55 (0.2-8.2)          | 1.6 (0.6-6.8)       | 0.968   |
| Procalcitonin (mcg/L)*  | -                   | -                   | -       | 0.63 (0.02-73.29)       | 0.73 (0.07-178)     | 0.216   |
| Other infections (n)(%) | 48 (87%)            | 40 (82%)            | 0.587   | -                       | -                   | -       |
| Surgeries (n)(%)        | 6 (11%)             | 4 (8%)              | 0.746   | -                       | -                   | -       |

SBP=systolic blood pressure, DBP=diastolic blood pressure, WBC=white blood cell, SCr=serum creatinine, CDI=*Clostridium difficile* infection, \*=median (interquartile range)

Table 3. Correlation between CDI and log PCT

|                     | r     | r <sup>2</sup> | P-value (2-tailed) |
|---------------------|-------|----------------|--------------------|
| Pearson correlation | 0.126 | 0.016          | 0.202              |

Figure 1. log PCT in CDI positive and negative




Table 4. Linear Regression

|                                 | Unstandardized coefficient | t     | P-value | 95% CI         |
|---------------------------------|----------------------------|-------|---------|----------------|
| CDI                             | 0.358                      | 2.02  | 0.047   | 0.01 to 0.71   |
| Surgery                         | -0.027                     | -0.1  | 0.925   | -0.6 to 0.54   |
| Probiotics                      | 0.006                      | 0.02  | 0.983   | -0.56 to 0.57  |
| log WBC                         | 0.356                      | 1.33  | 0.188   | -0.18 to 0.89  |
| log SCr                         | 0.653                      | 2.48  | 0.015   | 0.13 to 1.18   |
| Albumin                         | -0.097                     | -0.56 | 0.578   | -0.44 to 0.25  |
| Hypotension                     | -0.271                     | -1.53 | 0.129   | -0.62 to 0.08  |
| Invasive infection <sup>‡</sup> | -0.482                     | -2.81 | 0.006   | -0.82 to -0.14 |

WBC=white blood cell, SCr=serum creatinine, CDI=*Clostridium difficile* infection, <sup>‡</sup>=non urinary tract or uncomplicated skin infections


Table 5. Median PCT and ANOVA based on infection severity

|                       | Mild-moderate(n=14) | Severe (n=12)   | Severe, Complicated (n=29) |
|-----------------------|---------------------|-----------------|----------------------------|
| Median PCT (IQR)      | 0.44 (0.07-6.83)    | 0.4 (0.09-3.88) | 1.05 (0.02-73.29)          |
| ANOVA 2.922 (p=0.063) |                     |                 |                            |

Table 6. Post Hoc test between severity levels

|               |                     | Mean diff | P-value |
|---------------|---------------------|-----------|---------|
| Mild-moderate | Severe              | -0.053    | 0.86    |
|               | Severe, complicated | -0.531    | 0.042   |
| Severe        | Mild-moderate       | 0.053     | 0.86    |
|               | Severe, complicated | -0.478    | 0.073   |

Figure 2. log PCT in different severity levels



## CONCLUSION

- CDI demonstrated a small, positive effect on PCT
- Higher PCT levels were found with severe, complicated infections compared to mild-moderate infections
- Elevated PCT levels in both groups may be due to confounding factors (other bacterial infections, surgeries, etc)
- Further studies in patients with only CDI are needed to better assess the relationship between PCT and CDI

## REFERENCES

- Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control and Hosp Epidemiology. May 2010;31(5):431-55
- Rao K, Walk ST, Micic D, et al. Procalcitonin levels associate with severity of *Clostridium difficile* infection. PLoS ONE. 2013;8(3):e58265.
- Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine. 2011. 9:107.
- Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. Am J Gastroenterol. 2013;108(4):478-98.

**Disclosure:** Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter:

All authors: Nothing to disclose  
Approved by the Loma Linda University Investigational Review Board